
For many the most influential doctor in the world: «New England Journal of Medicine»-editor Eric Rubin.
You recently got a letter from the acting Attorney General in D.C.. Have you faced political pressure threatening editorial independence?
Yes, but we view our editorial work as strongly protected by the First Amendment, which guarantees freedom of the press in the United States. Medical journals, like newspapers, benefit from some of the most robust constitutional protections for free expression. In these situations, we remain focused on our robust editorial process and our commitment to publishing evidence-based science, confident that these constitutional safeguards help ensure our editorial independence
You’re also a Harvard professor. How has the current political situation affected research there?
Institutions like Harvard are at the leading edge of scientific research and innovation, so changes in the political landscape and funding priorities can have significant impacts. Many of us lost NIH grants, and these kinds of funding cuts don’t just affect individual researchers —they can slow progress across entire fields and limit the ability to make discoveries that benefit society as a whole. Sustained support for research is essential for advancing science and improving public health, both at Harvard and at institutions around the world.
The line between science and politics has become dangerously blurred. Can we still trust official guidelines when they sometimes change with political leadership?
When misinformation is mixed with political agendas, it can have serious consequences for public health and society at large. That’s why it’s essential for science to remain evidence-based and for trusted sources to communicate clearly and transparently.
It’s also important to distinguish scientific evidence from policy decisions. For example, during the COVID-19 pandemic, science could show that increased contact spreads disease, but whether to implement lockdowns was ultimately a political decision involving trade-offs like education and economic impact. Science should inform policy, but it does not dictate it; maintaining this distinction is crucial for public trust and effective decision-making.

A man of many hats
Eric Rubin
is the editor-in-chief of the New England Journal of Medicine, a researcher, and a professor of medicine at the elite American university Harvard. In addition to his medical training, he also studied molecular biology. As a scientist, he became known primarily for his research on genetic engineering methods applied to the tuberculosis bacterium. (smr)
In recent years, science has become more politicized — on topics like COVID or Roe v. Wade. Some Journals have started taking more political stands. Is that a good development?
Medical journals play an important role in facilitating informed discussion and debate on complex issues, including those that may intersect with politics. At NEJM, our primary focus is on publishing high-quality medical research and expert perspectives that are relevant to clinical practice and support patient care. While we recognize that politics often impact medical care and public health, our editorial decisions are guided by scientific merit and integrity, hence not by political considerations.
So, your stance is to remain apolitical?
We rarely issue editorial opinions on behalf of the journal itself; during my tenure, this has occurred only in exceptional circumstances, such as during the COVID-19 pandemic when we believed it was necessary for public health. Most opinions published in NEJM are authored by external contributors, undergo rigorous peer review, and are featured in our Perspectives section, which highlights topics of importance to practicing physicians. It’s important that we serve as a platform to encourage open and scholarly debate on prominent issues in medicine and public health, but our editorial focus remains on the science.
How do you decide whether to engage with topics that are both political and scientific?
We evaluate everything that is submitted. When a topic is both political and scientific, our decisions are guided by the rigor of the scientific evidence and its relevance to patient care, recognizing that politics often influence medical care and public health policy. We welcome research that challenges prevailing views, provided the science is rigorous and the methodology sound. When a paper questions established medical consensus, we apply the same strict standards of evidence and peer review, with careful attention to whether the claims are truly supported by data. If those standards are met, we are eager to publish work that advances — or even disrupts current thinking.
You have been the editor-in-chief of the New England Journal of Medicine NEJM for almost 6 years now. What has changed in the world of science since you started?
I became editor in September 2019, and before I could settle in, COVID hit. So, I have no «pre-pandemic baseline» to compare to. But certainly, COVID-19 dramatically increased both the volume and speed of scientific publishing. Early in the pandemic, there were few randomized trials available, so we published the best available data to help guide clinical decisions, always with the goal of supporting patient care in a rapidly evolving situation.
Let’s talk AI. There’s been a rapid rise in AI use in healthcare. According to a study done by the American Medical Association, 66% of doctors already use AI in daily practice. That number more than doubled within a year. What’s NEJM’s stance on AI in practice and research?
When it comes to studies, we’re certainly excited about the potential of AI to advance research, but we also feel strongly about enforcing our AI policies. For NEJM, authors must disclose any use of AI tools in preparing manuscripts, remain fully responsible for accuracy and originality, and cannot list AI tools as authors or cite AI-generated material as a primary source.
We also have NEJM AI, a journal dedicated to exploring how AI is shaping medical research, clinical practice, and healthcare delivery. More broadly, the practical application of AI in diagnosing and treating patients is a rapidly evolving field, but it comes with risks around accuracy, ethics, and patient safety. That’s one of the reasons why NEJM Group has signed a multi-year content agreement with OpenEvidence, an AI-powered medical search platform for clinicians. This partnership ensures that OpenEvidence delivers answers based on trusted, peer-reviewed content from NEJM journals, supporting innovation while maintaining accuracy, safety, and trust as AI is increasingly applied in clinical decision-making.
Do you think AI will transform scientific publishing?
Absolutely. We’re only at the beginning. Many routine publishing tasks will be handled by AI. Just like PubMed revolutionized accessibility, AI will be another major leap. It will streamline the routine parts of manuscript processing and preparation. Machine learning already plays a big role in studies that work with huge amounts of data. It will make it easier to ask better questions of large datasets, for example. That’s where we might see the biggest impact.
Some countries are restricting scientific collaboration. How does the New England Journal of Medicine handle submissions from states in political disrepute, like Russia?
We do receive some submissions from Russia, though historically not many. For us, the key consideration is always ethics and scientific rigor. We review all manuscripts based on the quality of the research and adherence to ethical standards, regardless of where the work originates. If a country’s ethical standards are weak, that could affect our confidence in the work and influence our editorial decisions. Our primary goal is to ensure that published research meets the highest standards of integrity and contributes meaningfully to medical knowledge.
There are many people who criticize the high costs for authors when submitting a paper – and the profit-orientation of publishing companies. What’s your view on open access publishing?
We don’t charge authors to submit or publish in NEJM. I believe people should have access to important studies, but open access has real downsides. First, the cost is most commonly shifted to authors, which can be prohibitively expensive. Second, journals that rely on author fees are incentivized to publish more articles, which can lower quality. We are highly selective, publishing about three percent of the articles submitted to us. That said, we offer free access in about 70–80 of the poorest countries. It’s a balance.
Also, it is important to note we’re a nonprofit. Our goal is credibility and sustainability over profitability. To further ensure our impartiality, we have strict policies: full-time editors can’t accept outside money, none of us can own healthcare stocks, and we recuse ourselves from reviewing manuscripts in cases of personal conflict. These policies help us stay impartial, guarded against commercial influence, and focused on scientific integrity.
How much influence does NEJM have on submitted papers, and do authors push back?
We don’t shape or dictate the original research, but we do set a high standard for scientific quality, ethics, and clarity. This often means asking authors for new data or analyses to back up their findings and sometimes requiring them to tone down or revise their conclusions if they’re not fully supported by the evidence. While we help ensure the integrity and clarity of the final paper, the core research remains the author’s own. With that said, sometimes authors do push back. Occasionally, if we can’t reach agreement on requested changes—like providing new data or revising conclusions—an author may choose to withdraw their paper, though that’s rare. Usually, we’re able to find a middle ground that satisfies both the authors and our editorial standards.
What’s your vision for the New England Journal of Medicine in the future?
Doctors and patients now get information from AI chatbots, Google, social media — not from only reading journal articles. That means we must meet people where they are: on phones, podcasts, videos. We want to maintain our scientific rigor but expand the way we communicate, so that reliable information reaches the people who need it most.




